Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Core Insights - Neuronetics, Inc. is a commercial stage medical technology company focused on transforming patient lives through neurohealth therapies [1][2] - The management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [1] Company Overview - Neuronetics is a global leader in neuroscience, providing innovative treatment options for mental health conditions [2] - The company offers the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for patients with major depressive disorder (MDD) when traditional medications are ineffective [2] - NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with over 7.4 million treatments delivered and supported by the largest clinical data set for TMS treatments [2] - Neuronetics operates Greenbrook TMS Inc., which runs treatment centers across the U.S. and has provided over 1.8 million treatments to more than 55,000 patients [2] Treatment Details - The NeuroStar Advanced Therapy System is FDA-cleared for adults with MDD and as an adjunct treatment for obsessive-compulsive disorder and anxiety symptoms in adults with MDD [3] - It is also approved as a first-line adjunct treatment for adolescents aged 15-21 with MDD [3]